Reply
To the Editors:
We appreciate the thoughtful response and largely agree with the points raised on serosorting for risk reduction and coercion. The focus of our article was to point out coerced testing in the context of expanding self-testing and the importance of promoting voluntary testing.
Negotiated safety arrangements between partners could be useful for HIV prevention. 1, 2 Within these settings, improving effective communication skills to persuade, rather than coerce, a partner to HIV test is important. An individual has the right to selfprotection when there is concern regarding a sexual partner's HIV serostatus and has the right to refuse sex with their partner who declines testing for HIV. However, this does not mean that they can force someone else to test for HIV against their will, even if it is ultimately for that person's benefit or good. We acknowledge that balancing an individual's right to self-protection and another's right to autonomy raises ethical conflicts and is not always easy to resolve. 3 The HIV self-testing guidelines of World Health Organization (WHO) and the Joint United Nations Programme on HIV/AIDS (UNAIDS) oppose coerced HIV test in any setting, including from sexual partners. 4 We acknowledge that what constitutes coercive testing is clear in its extreme manifestations but is less well defined when it overlaps with pressured testing that may be motivated by altruism or self-protection. To explore the nuances of how men defined and experienced coerced HIV testing, we subsequently conducted a mixedmethod study in the same cohort. This study found that pressure to test for HIV occurs on a spectrum, with clear instances of coercion (eg, threats to lose employment). At the same time, we also found examples where a man pressured his partner to receive an HIV test "in the name of love." 5 The main conclusion of our letter is about highlighting the possibility for coerced testing, especially in decentralized settings. To be clear, we agree that men have the right to withhold sex as part of an HIV risk reduction strategy. Further research is needed to better understand the risk of coerced HIV testing in diverse settings. 6 Jason J. Ong, PhD* † ‡ Chongyi Wei, DrPH § Stephen Pan, PhD † ‡ §k Hongyun Fu, PhD † ‡ §k ¶ Joseph D. Tucker, PhD* †# [1] [2] [3] Thus, we sought (1) to determine the prevalence of ZIKV exposure in an HIV/hepatitis B virus (HBV)-infected cohort in Ghana, West Africa, an area where ZIKV is believed to be endemic and (2) to identify laboratory and clinical correlates of infection in the setting of HIV-associated immunosuppression. Many viruses exhibit alterations of natural history in the setting of HIV. For example, the hepatitis C virus demonstrates increased rates of chronicity, higher viral loads, and accelerated liver injury in those with HIV. Dengue virus antibody was also evaluated because it was believed to be a common infection in West Africa, and its presence could lead to false positive reactions with ZIKV antibody tests.
METHODS

Clinical Samples
Two hundred thirty-six human sera infected with HIV and HBV were used. They were collected from a patient population who were receiving care at Korle-Bu teaching Hospital in Accra, Ghana, between 2012 and 2014. 4 The sample collection was part of a study of HBV treatment outcomes in the setting of HIV coinfection. Informed consent for creation of a sample repository and associated clinical data was obtained from all patients. Deidentified samples were sent to the University of Cincinnati College of Medicine for Zika/dengue testing and evaluation.
Quantitative Reverse Transcription Polymerase Chain Reaction
Viral RNA was extracted from sera using the QIAmp Ultrasense virus kit (Qiagen, Valencia, CA). RNA was quantified by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) using a commercial kit using proprietary primers designed to amplify ZIKV RNA (MyBioSource, San Diego, CA). The kit included an internal control used during the nucleic acid extraction process to verify the presence of amplifiable RNA and to identify possible RT-PCR inhibition. Viral RNA from sera also was screened by nested RT-PCR using degenerate primers targeting a region of the NS5 gene that is conserved among 60 different flaviviruses. 5 
ZIKV NS1-specific EnzymeLinked Immunosorbent Assay
IgM and IgG ZIKV-specific antibody responses were assessed using the Euroimmun diagnostic kit assay. Briefly, a 1:100 dilution of serum was performed in duplicate and added to precoated plates. The assay was performed after the manufacturer's instructions, with photometric measurements taken at 450 nm. All ZIKV IgG-positive samples and a subset of ZIKV negatives were evaluated for IgG DENV-specific antibody responses using the Abcam (Abcam, Cambridge, MA) antidengue IgG enzyme-linked immunosorbent assay kit.
Plaque Reduction Neutralization Test (PRNT)
Titers of neutralizing antibody to ZIKV and DENV were determined by Plaque Reduction Neutralization Test (PRNT) on Vero cells (ATCC #CCL-81) with a cutoff value of 90% (PRNT 90 ). 6 Neutralization curves were generated using GraphPad Prism software, and the resulting data were analyzed by nonlinear regression to estimate the dilution of serum required to inhibit 90% of infection. We considered a patient to have confirmed ZIKV exposure if ZIKV PRNT 90 was at least 20 and a ratio of ZIKV PRNT 90 to DENV PRNT 90 titer of at least 4.
RESULTS
During 2012-2014, 236 patients receiving care for HIV/HBV coinfection at the Korle-Bu teaching Hospital in Accra, Ghana, agreed to participate in the research study. The study population was 41% male with a mean age of 40.9 years. Sixty-five percent were using antiretroviral therapy, and the remainder were antiretroviral therapy naive. The median CD4 count was 436 cells/mm 3 . The WHO HIV stage distribution was as follows: 1%-24%; 2%-25%; 3%-39%; and 4%-12%. The mean serum alanine aminotransferase was 35 U/mL.
The samples were analyzed at the University of Cincinnati by quantitative RT-PCR to detect ZIKV RNA and nested RT-PCR to detect flavivirus RNA. No ZIKV RNA nor any flavivirus RNA was detected in any of the 236 samples.
To evaluate the potential likelihood of recent and previous exposure, samples were screened for the presence of ZIKV antibody. Of the 236 samples, 29 (12.3%) were anti-ZIKV IgG positive. By contrast, DENV IgG was much more common, occurring in 87.2% of tested individuals (n = 82). In addition, 2 samples (3%) were also anti-ZIKV IgM positive, which is suggestive of a recent exposure. However, the duration of ZIKV IgM antibodies in serum remains unknown, and positive results could be confounded by cross-reactivity with related flaviviruses. Indeed, both patient samples that were ZIKV IgM positive also were DENV IgG positive; and 100% of ZIKV IgG positive samples also were DENV IgG positive. However, the Euroimmune NS-1 anti-ZIKV IgG and IgM enzyme-linked immunosorbent assay tests have been reported to be highly specific and reliable for use in individuals with previous vaccination or flavivirus exposure. Serum panels from that study showed no cross-reactivity with Chikungunya, dengue, tick-borne encephalitis virus, yellow fever, or West Nile virus. 7 To further characterize the association with DENV, we performed PRNT on a subset of ZIKV-positive and ZIKV-negative samples. This included 8 suspected ZIKV exposures and 5 ZIKV negative but DENV antibody-positive samples. Among the 8 suspected ZIKV positives, 5 were confirmed ZIKV positive, 1 was confirmed ZIKV negative, but DENV positive, and the remaining 2 were both ZIKV and DENV negative (Fig. 1) . In the group of DENV antibody positive, ZIKV antibody negative samples, 3 of 5 were confirmed to be DENV positive, and 1 was classified as indeterminate. The fifth sample was negative for DENV neutralization.
The median CD4 of IgG-positive patients was 466 cells/mm 3 . In a multivariable least squares linear regression analysis, age, sex, WHO HIV stage, CD4, serum alanine aminotransferase, HIV viral load, and HBV viral load were not associated with ZIKV antibody positivity. By contrast, regional ethnicity (P = 0.02) seemed to be associated with ZIKV IgG positivity in the model. The highest rates were observed in the Greater Accra and Upper East regions.
DISCUSSION
In summary, ZIKV antibody was detected in 12.3% in HIV-infected persons attending a teaching hospital HIV clinic in Accra, Ghana. Dengue virus is endemic in that region as shown by all ZIKV antibody-positive persons having evidence of previous dengue infection as well. Priyamvada et al 8 noted high levels of cross-reaction between dengue antibodies and ZIKV and suggested that such antibodies could modulate ZIKV infections. Indeed, flavivirus field research is complicated by issues of cross-reactivity between many closely related viruses. Plaque reduction neutralization testing confirmed ZIKV seropositivity in 5 samples. It is most likely that most subjects have been exposed to both Zika and dengue as the prevalence of dengue antibody is much higher than that observed for ZIKV antibody. The true prevalence of ZIKV in this HIVinfected population cannot be definitively determined but seems to be significant. The multivariable model identified regional ethnicity as a highly significant factor in ZIKV antibody reactivity. The highest rates were observed in those originating from the Greater Accra and Upper East regions of the country. We are unable to determine whether the regional ethnicities are associated with lifestyle or environmental condition, which provide greater exposure to ZIKV. Other limitations of our study include the lack of PRNT testing for ZIKV and DENV in all positive samples, as this is a labor-intensive process. The lack of detectable ZIKV viremia is reassuring, suggesting that despite frequent virus exposure, chronicity evidenced by viremia is not a key feature of infection in those with HIV. However, recent data do suggest that ZIKV does persist in protected compartments in immunocompetent patients, 9 and we would suspect that this might be more frequent in those with HIV.
As the ZIKV epidemic in the Americas wanes, it will become increasingly important to understand cofactors that might predispose an individual to more severe or even chronic disease. This in turn can help direct limited resources to populations most at risk. Indeed, the NIH recently initiated an international, multisite clinical study, "Prospective Cohort Study of HIV and Zika in Infants and Pregnancy" (HIV ZIP; ClinicalTrials. gov identifier NCT03263195) to enroll 2000 pregnant women to study ZIKV/ HIV comorbidity in the continental United States, Brazil, and Puerto Rico. Still, more information is needed on the prevalence of ZIKV in Africa because a growing body of evidence suggests that, in Africa, a Zika epidemic could be undetected and/or overlooked. Studies have claimed to show widespread exposure to Zika in at least 25 countries across Africa, but overall data regarding the prevalence of ZIKV infection in Africa have been limited. Herrera et al reported that Zika virus IgM prevalence was 6.2% in cohorts derived from patients in Senegal and Nigeria and suggest that ZIKV has been silently circulating in West Africa for at least 20 or more years. 10, 11 These cohorts included more than 200 HIV-positive patients. The data presented herein highlight the critical need for accurate laboratory diagnostics and suggest that proper surveillance activities regarding ZIKV in sub-Saharan Africa are imperative.
In a "Hot News" editorial commentary about ZIKV in AIDS reviews, Barreiro However, the authors also label as coercion an individual's decision to abstain from having sex with a partner who refuses HIV testing, and we strongly disagree. We would argue that an individual has a right to refuse to engage in sex with someone who they believe may put them at risk of HIV infection; more generally, we also argue that an individual has a basic right to refuse to have sex.
Our research over the past 10 years has demonstrated that men who have sex with men who seldom or never use condoms often use serosorting (having sex only with partners known or perceived to be of one's same HIV status) to reduce the risk of HIV transmission. 1 To serosort more accurately, these men also are willing to use rapid HIV tests with potential partners to clarify their respective HIV statuses (notwithstanding a recent infection that may not be detected by the test). 2 Participants in our most recently completed study tested 7 potential sexual partners with whom they had discussed engaging in "raw" or "bareback" sex (condomless anal intercourse) who received HIVpositive results and who seemed to be unaware of their infection. There was no sexual encounter after test results were revealed. In these situations, use of a rapid HIV test with these partners may have directly impeded HIV infection. 3 Other study participants reported that they came to view a partner's refusal to use a rapid HIV self-test as a sign of the partner's concern about their sexual risk behavior and lack of certainty about their HIV status. As a result, they considered that individual to pose a high risk of HIV infection, and unless the individual agreed to an HIV test, they did not engage in sex. 4 This self-protective act is no different than withholding sex from a partner who refuses to use condoms. Yet, under the definition proposed by Ong et al, it would also be considered coercion. We see the issue not as one of "force" but of "harm" and the individual's right to self-protection, in this specific case from HIV infection, which Ong et al entirely downplay in their letter.
We recognize that this study, conducted among men who have sex with men in China, needs to be culturally contextualized, which might introduce differences in perceptions of coercion and nuances in the terminology used to assess coercion. However, the authors' conclusion-that withholding sex from a partner who refuses to have an HIV test constitutes coercion-could stigmatize an important risk-reduction strategy and discourage the deployment of this promising tool for self-care in settings where the likelihood of HIV acquisition remains high. 
